Health
Virus drug benefit only marginal: study – Tenterfield Star
Moderately ill COVID-19 patients had their condition improve after a 5-day course of Gilead Sciences Inc’s remdesivir but the drug did not significantly short…
Moderately ill COVID-19 patients had their condition improve after a 5-day course of Gilead Sciences Inc’s remdesivir but the drug did not significantly shorten hospital stays and a 10-day course did not show a benefit, according to new data.
The drug, which was shown in a trial of severely ill COVID-19 patients to shorten their hospital recovery time, has been at the forefront of the battle against the pandemic.
The 600-patient analysis, published on Friday by the Journal of the American Medi…
-
General11 hours agoICAC investigating University of Wollongong as chancellor grilled at Inquiry
-
General20 hours agoTwo people arrested after man fatally shot at McLaren Flat
-
General18 hours agoWarner Bros Discovery board rejects rival $163bn bid from Paramount
-
General9 hours agoCoalition ‘flabbergasted’ by Labor’s response to calls for royal commission into antisemitism